Humana (HUM) Stock Forecast & Price Target

$290.65 -0.65 (-0.22%)

Closing price 10/24/2025 03:59 PM Eastern

Extended Trading

$293.05 +2.40 (+0.82%)

As of 10/24/2025 07:48 PM Eastern

Compare

Humana - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Hold

Based on 20 Analyst Ratings

Sell
2

Hold
10

Buy
8

Based on 20 Wall Street analysts who have issued ratings for Humana in the last 12 months, the stock has a consensus rating of "Hold." Out of the 20 analysts, 2 have given a sell rating, 10 have given a hold rating, and 8 have given a buy rating for HUM.

Consensus Price Target

$297.58
2.38% Upside

According to the 20 analysts' twelve-month price targets for Humana, the average price target is $297.58. The highest price target for HUM is $347.00, while the lowest price target for HUM is $235.00. The average price target represents a forecasted upside of 2.38% from the current price of $290.66.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for HUM and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Humana and its competitors.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

HUM Analyst Ratings Over Time

Type	Current Forecast 10/25/24 to 10/25/25	1 Month Ago 9/25/24 to 9/25/25	3 Months Ago 7/27/24 to 7/27/25	1 Year Ago 10/26/23 to 10/25/24
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	8 Buy rating(s)	7 Buy rating(s)	7 Buy rating(s)	6 Buy rating(s)
Hold	10 Hold rating(s)	17 Hold rating(s)	16 Hold rating(s)	18 Hold rating(s)
Sell	2 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$297.58	$289.50	$282.43	$315.33
Forecasted Upside	2.38% Upside	13.82% Upside	18.56% Upside	20.94% Upside
Consensus Rating	Hold	Hold	Hold	Hold

HUM Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

HUM Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Humana Stock vs. The Competition

Type	Humana	Medical Companies	S&P 500
Consensus Rating Score	2.30	2.33	2.52
Consensus Rating	Hold	Hold	Moderate Buy
Predicted Upside	2.38% Upside	1,391.91% Upside	12.10% Upside
News Sentiment Rating	Positive News See Recent HUM News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
10/14/2025	Truist Financial 3 of 5 stars	David MacDonald 2 of 5 stars	Set Target		$300.00	+14.45%
10/14/2025	The Goldman Sachs Group 3 of 5 stars	Scott Fidel Not Rated	Initiated Coverage	Buy ➝ Sell	$235.00	-13.23%
10/10/2025	Bank of America 4 of 5 stars	Kevin Fischbeck Not Rated	Boost Target	Neutral	$280.00 ➝ $300.00	+5.92%
10/9/2025	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ann Hynes Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$300.00 ➝ $345.00	+15.67%
10/8/2025	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Sell (D+)
10/7/2025	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Stephen Baxter Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$344.00 ➝ $347.00	+17.25%
10/6/2025	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Outperform	$283.00 ➝ $313.00	+11.69%
10/3/2025	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Andrew Mok Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Equal Weight	$315.00 ➝ $245.00	-4.62%
10/3/2025	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jason Cassorla Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy
9/22/2025	Evercore ISI Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Elizabeth Suzuki Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	In-Line	$295.00	+16.88%

9/5/2025	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lance Wilkes Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$269.00 ➝ $341.00	+9.66%
8/21/2025	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ben Hendrix Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$283.00 ➝ $322.00	+10.54%
7/31/2025	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Erin Wright Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Equal Weight	$290.00 ➝ $277.00	+10.26%
7/31/2025	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jessica Tassan Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Neutral	$288.00 ➝ $272.00	+6.39%
7/25/2025	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Ha Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Neutral	$300.00 ➝ $297.00	+29.42%
5/1/2025	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Sarah James Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Neutral	$290.00 ➝ $290.00	+11.86%
5/1/2025	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Wiederhorn Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$300.00 ➝ $310.00	+19.44%
5/1/2025	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	J. Ransom Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$315.00	+20.04%
2/18/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lisa Gill Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Neutral	$257.00 ➝ $256.00	-0.16%
11/4/2024	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	R. Langston Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Hold	$261.00 ➝ $268.00	+5.16%
10/11/2024	KeyCorp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	M. Gillmor Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Sector Weight
10/9/2024	Stephens Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	S. Fidel Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Equal Weight	$250.00 ➝ $250.00	+2.35%
10/7/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Buy ➝ Hold	$519.00 ➝ $253.00	+5.40%
10/4/2024	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Neutral	$380.00 ➝ $250.00	+3.31%
10/3/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Hold	$349.00 ➝ $250.00	+3.70%
10/2/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	W. Mayo Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
10/2/2024	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform	$400.00 ➝ $250.00	+6.05%
5/30/2024	Baird R W Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	M. Ha Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Hold
3/13/2024	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Buy ➝ Hold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 02:19 AM ET.

Should I Buy Humana Stock? HUM Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, October 16, 2025. Please send any questions or comments about these Humana pros and cons to contact@marketbeat.com.

Humana
Bull Case

Here are some ways that investors could benefit from investing in Humana Inc.:

The current stock price is around $298, reflecting a stable position in the market.
Humana Inc. reported a significant revenue increase of 9.6% compared to the same quarter last year, indicating strong business growth.
The company has a solid return on equity of 13.67%, showcasing effective management and profitability.
Humana Inc. has a relatively low dividend payout ratio of 27.17%, suggesting that it retains a good portion of its earnings for reinvestment, which can lead to future growth.
Analysts have a generally favorable outlook, with several recent upgrades to price targets, indicating confidence in the company's future performance.

Humana
Bear Case

Investors should be bearish about investing in Humana Inc. for these reasons:

The stock has received a "sell" rating from Weiss Ratings, which may indicate potential risks in the investment.
Some analysts have significantly lowered their price targets, suggesting a lack of confidence in short-term performance.
Humana Inc. reported earnings per share that missed analysts' expectations, which could raise concerns about its profitability.
The company has a net margin of only 1.28%, which may indicate challenges in maintaining profitability amidst rising costs.
Market volatility could impact Humana Inc.'s stock performance, as indicated by its beta of 0.42, suggesting it is less volatile than the market but still subject to fluctuations.

HUM Forecast - Frequently Asked Questions

: According to the research reports of 20 Wall Street equities research analysts, the average twelve-month stock price forecast for Humana is $297.58, with a high forecast of $347.00 and a low forecast of $235.00.
: 20 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Humana in the last year. There are currently 2 sell ratings, 10 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" HUM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HUM, but not buy additional shares or sell existing shares.
: According to analysts, Humana's stock has a predicted upside of 2.38% based on their 12-month stock forecasts.
: Humana has been rated by research analysts at Bank of America, Barclays, Evercore ISI, Guggenheim, Mizuho, Morgan Stanley, Piper Sandler, Royal Bank Of Canada, Sanford C. Bernstein, The Goldman Sachs Group, Truist Financial, Weiss Ratings, Wells Fargo & Company, and Wolfe Research in the past 90 days.
: Analysts like Humana less than other "medical" companies. The consensus rating score for Humana is 2.30 while the average consensus rating score for "medical" companies is 2.33. Learn more on how HUM compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:HUM) was last updated on 10/25/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Humana (HUM) Stock Forecast & Price Target